Martin Kaufmann1, J Christopher Gallagher, Munro Peacock, Karl-Peter Schlingmann, Martin Konrad, Hector F DeLuca, Rita Sigueiro, Borja Lopez, Antonio Mourino, Miguel Maestro, René St-Arnaud, Joel S Finkelstein, Donald P Cooper, Glenville Jones. 1. Department of Biomedical and Molecular Sciences (M.Ka., G.J.), Queen's University, Kingston, Ontario, Canada K7L 3N6; Bone Metabolism Unit (J.C.G.), Creighton University School of Medicine, Omaha, Nebraska 68131; Indiana University School of Medicine (M.P.), Indianapolis, Indiana 46202-5250; Department of General Pediatrics, (K-P. S., M.Ko.) University Children's Hospital, D-48149, Münster, Germany; Department of Biochemistry (H.F.D.), University of Wisconsin-Madison, Madison, Wisconsin 53706; Departmento de Quimica Organica (R.S., B.L., A.M., M.M.), Laboratorio Ignacio Ribas, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; McGill University and Shriners Hospital for Children-Canada (R.S.), Montréal, Québec, Canada H3G 1A6; Endocrine Unit (J.S.F.), Massachusetts General Hospital, Boston Massachusetts 02114; and Health Sciences Research, Waters Corporation (D.P.C), Stamford Avenue, Altrincham Rd, Wilmslow, SK9 4AX United Kingdom.
Abstract
CONTEXT: The discovery of hypercalcemic diseases due to loss-of-function mutations in 25-hydroxyvitamin D-24-hydroxylase has placed a new demand for sensitive and precise assays for 24,25-dihydroxyvitamin D [24,25-(OH)2D]. OBJECTIVE: We describe a novel liquid chromatography and tandem mass spectrometry-based method involving derivatization with DMEQ-TAD {4-[2-(6,7-dimethoxy-4-methyl-3,4-dihydroquinoxalinyl)ethyl]-1,2,4-triazoline-3,5-dione} to simultaneously assay multiple vitamin D metabolites including 25-hydroxyvitamin D (25-OH-D) and 24,25-(OH)2D using 100 μL of serum with a 5-minute run time. DESIGN: The assay uses a newly synthesized internal standard d6-24,25-(OH)2D3 enabling the quantitation of 24,25-(OH)2D3 as well as the determination of the ratio of 25-OH-D3 to 24,25-(OH)2D3, a physiologically useful parameter. SETTING: We report data on more than 1000 normal and disease samples involving vitamin D deficiency or hypercalcemia in addition to studies involving knockout mouse models. RESULTS: The assay showed good correlation with samples from quality assurance schemes for 25-OH-D (25-OH-D2 and 25-OH-D3) determination (-2% to -5% bias) and exhibited low inter- and intraassay coefficients of variation (4%-7%) and lower limits of quantitation of 0.25-0.45 nmol/L. In clinical studies, we found a strong correlation between serum levels of 25-OH-D3 and 24,25-(OH)2D3 (r(2) = 0.80) in subjects over a broad range of 25-OH-D3 values and a marked lack of production of 24,25-(OH)2D3 below 25 nmol/L of 25-OH-D. The ratio of 25-OH-D3 to 24,25-(OH)2D3, which remained less than 25 in vitamin D-sufficient subjects (serum 25-OH-D < 50 nmol/L) but was greatly elevated (80-100) in patients with idiopathic infantile hypercalcemia. CONCLUSIONS: The new method showed good utility in clinical settings involving vitamin D deficiency; supplementation with vitamin D and idiopathic infantile hypercalcemia, as well as in animal models with ablation of selected cytochrome P450-containing enzymes involved in vitamin D metabolism.
CONTEXT: The discovery of hypercalcemic diseases due to loss-of-function mutations in 25-hydroxyvitamin D-24-hydroxylase has placed a new demand for sensitive and precise assays for 24,25-dihydroxyvitamin D [24,25-(OH)2D]. OBJECTIVE: We describe a novel liquid chromatography and tandem mass spectrometry-based method involving derivatization with DMEQ-TAD {4-[2-(6,7-dimethoxy-4-methyl-3,4-dihydroquinoxalinyl)ethyl]-1,2,4-triazoline-3,5-dione} to simultaneously assay multiple vitamin D metabolites including 25-hydroxyvitamin D (25-OH-D) and 24,25-(OH)2D using 100 μL of serum with a 5-minute run time. DESIGN: The assay uses a newly synthesized internal standard d6-24,25-(OH)2D3 enabling the quantitation of 24,25-(OH)2D3 as well as the determination of the ratio of 25-OH-D3 to 24,25-(OH)2D3, a physiologically useful parameter. SETTING: We report data on more than 1000 normal and disease samples involving vitamin Ddeficiency or hypercalcemia in addition to studies involving knockout mouse models. RESULTS: The assay showed good correlation with samples from quality assurance schemes for 25-OH-D (25-OH-D2 and 25-OH-D3) determination (-2% to -5% bias) and exhibited low inter- and intraassay coefficients of variation (4%-7%) and lower limits of quantitation of 0.25-0.45 nmol/L. In clinical studies, we found a strong correlation between serum levels of 25-OH-D3 and 24,25-(OH)2D3 (r(2) = 0.80) in subjects over a broad range of 25-OH-D3 values and a marked lack of production of 24,25-(OH)2D3 below 25 nmol/L of 25-OH-D. The ratio of 25-OH-D3 to 24,25-(OH)2D3, which remained less than 25 in vitamin D-sufficient subjects (serum 25-OH-D < 50 nmol/L) but was greatly elevated (80-100) in patients with idiopathic infantile hypercalcemia. CONCLUSIONS: The new method showed good utility in clinical settings involving vitamin D deficiency; supplementation with vitamin D and idiopathic infantile hypercalcemia, as well as in animal models with ablation of selected cytochrome P450-containing enzymes involved in vitamin D metabolism.
Authors: Ravinder J Singh; Robert L Taylor; G Satyanarayana Reddy; Stefan K G Grebe Journal: J Clin Endocrinol Metab Date: 2006-05-23 Impact factor: 5.958
Authors: Galina Nesterova; May Christine Malicdan; Kaori Yasuda; Toshiyuki Sakaki; Thierry Vilboux; Carla Ciccone; Ronald Horst; Yan Huang; Gretchen Golas; Wendy Introne; Marjan Huizing; David Adams; Cornelius F Boerkoel; Michael T Collins; William A Gahl Journal: Clin J Am Soc Nephrol Date: 2013-01-04 Impact factor: 8.237
Authors: Debin Wan; Jun Yang; Bogdan Barnych; Sung Hee Hwang; Kin Sing Stephen Lee; Yongliang Cui; Jun Niu; Mitchell A Watsky; Bruce D Hammock Journal: J Lipid Res Date: 2017-02-01 Impact factor: 5.922
Authors: Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley Journal: Br J Clin Pharmacol Date: 2018-07-17 Impact factor: 4.335
Authors: Mandy E Turner; Christine A White; Sarah M Taylor; Kathryn Neville; Karen Rees-Milton; Wilma M Hopman; Michael A Adams; Tassos Anastassiades; Rachel M Holden Journal: Calcif Tissue Int Date: 2021-01-22 Impact factor: 4.333
Authors: Karl P Schlingmann; Justyna Ruminska; Martin Kaufmann; Ismail Dursun; Monica Patti; Birgitta Kranz; Ewa Pronicka; Elzbieta Ciara; Teoman Akcay; Derya Bulus; Elisabeth A M Cornelissen; Aneta Gawlik; Przemysław Sikora; Ludwig Patzer; Matthias Galiano; Veselin Boyadzhiev; Miroslav Dumic; Asaf Vivante; Robert Kleta; Benjamin Dekel; Elena Levtchenko; René J Bindels; Stephan Rust; Ian C Forster; Nati Hernando; Glenville Jones; Carsten A Wagner; Martin Konrad Journal: J Am Soc Nephrol Date: 2015-06-05 Impact factor: 10.121
Authors: Gina N Woods; Alec Saitman; Hanlin Gao; Nigel J Clarke; Robert L Fitzgerald; Nai-Wen Chi Journal: J Bone Miner Res Date: 2016-05-06 Impact factor: 6.741
Authors: D P Larner; C Jenkinson; R F Chun; C S J Westgate; J S Adams; M Hewison Journal: J Steroid Biochem Mol Biol Date: 2019-01-30 Impact factor: 4.292
Authors: Anders H Berg; Camille E Powe; Michele K Evans; Julia Wenger; Guillermo Ortiz; Alan B Zonderman; Pirianthini Suntharalingam; Kathryn Lucchesi; Neil R Powe; S Ananth Karumanchi; Ravi I Thadhani Journal: Clin Chem Date: 2015-04-28 Impact factor: 8.327
Authors: Mark B Meyer; Nancy A Benkusky; Martin Kaufmann; Seong Min Lee; Robert R Redfield; Glenville Jones; J Wesley Pike Journal: J Biol Chem Date: 2019-05-03 Impact factor: 5.157